MOTS-C is a chain of 16 amino acids (sequence MRWQEMGYIFYPRKLR). This is an identity fact, not a product claim.
Lee et al., Cell Metabolism, 2015Plain-English research guideMOTS-C / MT-RNR1 sORF
MOTS-C research guide
Everything worth knowing, without the jargon.
MOTS-C is a 16-amino-acid mitochondrial-derived peptide (MDP) - one of a small family of peptides encoded inside mitochondrial DNA, in the 12S rRNA (MT-RNR1) region. First described in 2015, it's studied in cell and animal research for mitochondrial biology and the AMPK energy pathway.
Form Labs materials are research reference materials, not the approved medicines; no Form Labs product is approved for human or veterinary use.
REV 2026-10 · 1 Oct 20265 peer-reviewed studiesResearch-use-only context
What the papers reportThird-party literature - not product claims
The year MOTS-C was first described, as one of a small family of peptides encoded inside mitochondrial DNA. This is research context, not a product claim.
Lee et al., Cell Metabolism, 2015The cell's main energy-sensing pathway (AMP-activated protein kinase). MOTS-C is most linked to this pathway across the research. This is research context, not a product claim.
Lee et al., Cell Metabolism, 2015Why it matters
Why is MOTS-C studied?
MOTS-C is studied because it is a mitochondrial-derived peptide (MDP) of 16 amino acids. Its gene sits inside mitochondrial DNA, in the 12S rRNA (MT-RNR1) region, not in the cell nucleus (Form Labs catalogue record). Lee and colleagues first described MOTS-C in 2015 (Lee et al., 2015). Most of the research in this guide is cell culture and rodent work. It looks at mitochondrial biology and the AMPK energy pathway. None of it gave native MOTS-C to people.
A peptide written in mitochondrial DNA.
Nearly every protein the body makes is encoded in the DNA inside the cell's nucleus. MOTS-C is unusual because its gene sits inside mitochondrial DNA. This is the small, separate genome of the mitochondria, the energy-handling parts inside the cell. That is what first drew researchers to it.
Lee and colleagues first described it in 2015. They found it in a short open reading frame in the mitochondrial 12S rRNA gene (the MT-RNR1 region). That made it one of a small, newly recognised family of mitochondrial-derived peptides. Humanin is another. The field is still young.
Most of what has been published since is cell culture and rodent research into mitochondrial biology and the AMPK energy pathway. There are no large human trials of the native peptide. So this guide uses all of it as research context. It is not something the vial will do for a person.
Study observations
What laboratory observations have MOTS-C studies reported?
Lee et al. (2015) reported AMPK pathway and insulin-sensitivity observations for MOTS-C in cell and mouse models, with no human data. Kim et al. (2018) reported MOTS-C moving into the nucleus under glucose restriction in cultured human cells. Cell-culture findings are separate from a clinical study in people.
MOTS-C laboratory observations Findings stay tied to the cited study and its model.
Mitochondrial origin
Lee et al. (2015) described MOTS-C as a mitochondrial-derived peptide in cell and mouse research.
Cell and mouse models
Lee et al. (2015) linked MOTS-C to the folate/one-carbon and AMPK pathways in cell and mouse models. The paper included no human data.
Cultured human cells
Kim et al. (2018) reported MOTS-C moving into the nucleus under glucose restriction in cultured human cells. This is a cell culture finding.
Pharmacology at a glance
- Research code
- MOTS-C / MT-RNR1 sORF
- Class
- Mitochondrial-derived peptide (MDP). It is a small peptide encoded inside mitochondrial DNA instead of the cell nucleus.
- Molecule
- A peptide of 16 amino acids, sequence MRWQEMGYIFYPRKLR, supplied as a freeze-dried powder.
- Reported half-life
- This guide records no established clinical half-life for MOTS-C.
- Originator
- Lee and colleagues first described it in 2015, from a short open reading frame in the mitochondrial 12S rRNA gene. Form Labs did not run the cited studies.
- Approval status
- Lab research material only. It is not an approved medicine. The TGA and other regulators have not evaluated it for human use.
What it has been studied for
What has MOTS-C been studied for?
MOTS-C research includes cell and mouse metabolism findings (Lee et al., 2015) and stress observations in cultured cells (Kim et al., 2018). It also includes exercise measures in mice and healthy men (Reynolds et al., 2021). The human observations measured the body's own MOTS-C. They were not a trial that gave people native MOTS-C.
Study areas from the published literature.
Metabolic homeostasis & AMPK
Activation of the AMPK energy-sensing pathway through folate/one-carbon metabolism, and insulin sensitivity in mice.
Lee et al., Cell Metabolism, 2015 (cells + mice)Mitonuclear stress signalling
Movement of MOTS-C into the nucleus under glucose restriction to regulate stress response genes.
Kim et al., Cell Metabolism, 2018 (cells)Exercise & age-related physical decline
Running capacity and physical performance in aged mice. One cycling bout raised the body's own MOTS-C in 10 healthy men.
Reynolds et al., Nature Communications, 2021 (mice + human exercise)Muscle function & CK2 (genetic association)
Binding and activation of CK2 in mice and cells. A natural gene variant linked to sarcopenia and type 2 diabetes risk across three human cohorts.
Kumagai et al., iScience, 2024 (mice + cells + human genetic)Circulating MOTS-C as a biomarker
Blood levels of MOTS-C measured against obesity and insulin resistance markers in young people.
Du et al., Pediatric Diabetes, 2018 (human observational)The studies
What did the MOTS-C studies find?
The five MOTS-C studies in this guide are mostly cell and mouse work. The human data is observational. Lee et al. (2015) reported that MOTS-C activated AMPK and was linked to better insulin sensitivity in mice, with no human data. Reynolds et al. (2021) found that one cycling bout raised the body's own MOTS-C in 10 healthy men. Du et al. (2018) found that circulating MOTS-C was lower in obese than non-obese children.
Open any study for a plain summary, what it measured, the finding, and a link to the paper.
The paper that first identified MOTS-C, from a short open reading frame in mitochondrial DNA. It linked MOTS-C to the AMPK energy pathway and to insulin sensitivity in mice.
- Studied in
- Human cell lines (HEK293, HeLa, L6) and mice.
- Design
- A discovery paper. Lab cell work plus animal experiments set out the peptide and its main pathway.
- Measured
- AMPK pathway activation, folate/one-carbon metabolism, and markers of insulin sensitivity in mice.
Lee et al. (2015) reported AMPK activation through the folate/one-carbon pathway in cells and more insulin sensitivity in mice. The paper included no human data.
DOI 10.1016/j.cmet.2015.02.009This paper showed that under glucose restriction MOTS-C moves into the cell nucleus. There it helps regulate stress response genes.
- Studied in
- Human cell lines (HEK293, HepG2) in culture.
- Design
- A cell culture study of where MOTS-C sits in the cell and which genes it touches under metabolic stress.
- Measured
- Movement of MOTS-C into the nucleus, and changes in the activity of stress- and antioxidant response genes (NRF2/AMPK).
Under glucose restriction, MOTS-C moved from the cytoplasm into the nucleus of the cultured cells. There it helped regulate antioxidant and stress response genes (Kim et al., 2018).
DOI 10.1016/j.cmet.2018.06.008This paper reported that aged mice given MOTS-C had better physical performance. It also reported that one bout of cycling raised the body's own MOTS-C in 10 healthy men.
- Studied in
- Aged mice, plus 10 healthy men for a measure of the body's own MOTS-C.
- Design
- Animal experiments on running capacity, grip and stride, plus a small human exercise observation. No MOTS-C was given to the men.
- Measured
- Running capacity, grip strength and stride in aged mice. The body's own MOTS-C levels after exercise in the men. Lifespan in mice.
Reynolds et al. (2021) reported differences in running capacity, grip and stride in aged mice. Separately, the body's own MOTS-C rose after cycling in 10 healthy men. The men did not receive MOTS-C. The mouse lifespan trend was not significant (P=0.05).
DOI 10.1038/s41467-020-20790-0This paper reported that MOTS-C binds and activates a protein called CK2. It also reported on a natural gene variant. The variant has weaker CK2 binding. It was linked to certain muscle and metabolic traits in large human cohorts.
- Studied in
- Mice and cell cultures, plus three human cohort datasets analysed for a genetic link.
- Design
- Lab work on how MOTS-C binds CK2, plus a genetic-association analysis of a natural MOTS-C variant. It was not a trial that gave MOTS-C to people.
- Measured
- CK2 binding and activation in mice and cells. Also the statistical link between the K14Q variant and the risk of sarcopenia and type 2 diabetes across the cohorts.
MOTS-C bound and activated CK2 in mice and cells (Kumagai et al., 2024). A natural MOTS-C gene variant (K14Q) has weaker CK2 binding. Across three human cohorts, it was associated with higher sarcopenia and type 2 diabetes risk. This is a genetic association rather than a clinical outcome for native MOTS-C.
DOI 10.1016/j.isci.2024.111212This paper measured MOTS-C in the blood of young people. It compared the levels across obesity and insulin resistance groups.
- Studied in
- Children and adolescents, grouped by obesity status.
- Design
- An observational biomarker study. It measured circulating MOTS-C and compared it across groups. No MOTS-C was given to anyone.
- Measured
- Blood levels of MOTS-C alongside insulin resistance and related metabolic markers.
Circulating MOTS-C was lower in obese than non-obese children and adolescents (Du et al., 2018). It also tracked with insulin resistance markers. This is a human observational measurement. It is not a trial that gave MOTS-C to anyone. It is a correlation in a population, not evidence of what the peptide does to a person.
DOI 10.1111/pedi.12685Where evidence stops
What has MOTS-C research not established?
The MOTS-C research in this guide has not included large human clinical trials. None of the cited studies gave native MOTS-C to people for any outcome. The cited literature does not establish human efficacy numbers. The research gives no direction for use in or on people or animals. It describes the molecule in general. It does not say what one batch does.
- Large human clinical trials: there is no peer-reviewed trial giving native MOTS-C to people for any outcome.
- Any use in or on people or animals: none of the research on this page is a use direction.
- What a specific batch does: the studies are about the molecule in general, not this vial.
Development and status
Is MOTS-C approved, and where does the research stand?
This guide describes MOTS-C as lab research material only. Its timeline begins with Lee and colleagues' description of MOTS-C (Lee et al., 2015). Next comes movement into the nucleus under glucose restriction (Kim et al., 2018). Then come mouse and exercise data (Reynolds et al., 2021) and CK2 binding (Kumagai et al., 2024).
MOTS-C is first described by Lee and colleagues, from a short open reading frame in mitochondrial DNA (Cell Metabolism).
Kim and colleagues report MOTS-C moving into the nucleus under glucose restriction to regulate stress response genes (Cell Metabolism).
Du and colleagues measure circulating MOTS-C against obesity and insulin resistance markers in young people (Pediatric Diabetes).
Reynolds and colleagues report better physical performance in aged mice given MOTS-C. They also report that exercise raises the body's own MOTS-C in 10 healthy men (Nature Communications).
Kumagai and colleagues map CK2 binding and activation. They also map a linked natural gene variant tied to muscle and metabolic traits (iScience).
Approval status: Lab research material only. It is not an approved medicine. The TGA and other regulators have not evaluated it for human use.Whatever the molecule’s status elsewhere, what Form Labs supplies is research-use-only reference material - for laboratory work, not for people or animals.
Evidence and limitations
What does the MOTS-C research mean, and what does it not?
The MOTS-C evidence comes from a young field. MOTS-C was first described in 2015 (Lee et al., 2015). The research in this guide is mostly cell cultures and mice. This does not turn into claims about people. The human-linked findings are observational or about the body's own MOTS-C. They cover exercise raising the body's own MOTS-C. They cover a gene variant linked to traits. They cover blood levels that track markers. None gave MOTS-C to people as a treatment.
It's a young field
MOTS-C was first described in 2015. Mitochondrial-derived peptides as a family are still new. The evidence is growing but small compared with longer-studied peptides.
Most evidence is cells and rodents
The published work is mostly cell cultures and mice. It is useful for understanding the molecule. But it does not turn into claims about people.
The human evidence is observational only
The human-linked findings are observational or about the body's own MOTS-C. Exercise raises the body's own MOTS-C (Reynolds). A gene variant is linked to traits (Kumagai). Blood levels track markers (Du). None gave MOTS-C to people as a treatment.
The lab report is the authority for a batch
Each lab report covers only the sample, amount and lot it names. Match the lot number on your vial to the reports in the certificate library.
Lab handling
How is MOTS-C handled as reference material?
MOTS-C is lab reference material. It is not for human consumption or veterinary use. Storage and lot checks follow the product label. They also follow any verified matching certificate of analysis (COA). The catalogue record notes storage at 2-8 C and protection from light.
Research-use boundary
MOTS-C is supplied strictly for lab research. It is not for human consumption, or for veterinary, medical or cosmetic use.
COA and label
The report on file for MOTS-C is an independent lab assessment of an earlier sample, measuring peptide content at 11.15 mg. It prints no purity percentage. It covers its named sample, not the current catalog lot.
Storage
Supplied freeze-dried. Store cold at 2-8 C (fridge-cold) and out of light. Follow the vial label, any verified matching lab report for the batch. The receiving lab's own written procedures.
Educational boundary
This guide is a plain summary of third-party research that Form Labs did not run. It is not medical advice or a product claim.
Glossary
Plain-English definitions.
- Mitochondrial-derived peptide (MDP)
- A small peptide encoded inside mitochondrial DNA instead of the cell's nuclear DNA. MOTS-C and humanin are examples.
- MT-RNR1
- The mitochondrial gene region that codes for the 12S rRNA. MOTS-C's short gene sits there.
- 12S rRNA
- A type of ribosomal RNA encoded by mitochondrial DNA. The MT-RNR1 gene makes it.
- sORF
- Short open reading frame. It is a short genetic section that can code for a small peptide, like MOTS-C.
- AMPK
- AMP-activated protein kinase. It is the cell's central energy-sensing pathway, and the one most linked to MOTS-C.
- Folate / one-carbon (AICAR) pathway
- A metabolic route that the 2015 paper linked to MOTS-C's activation of AMPK.
- Mitonuclear
- Describing communication between the mitochondria and the cell nucleus. It is relevant to MOTS-C's move into the nucleus under stress.
- CK2
- A protein kinase (enzyme) that MOTS-C binds and activates, as reported in 2024 lab work.
- GLUT4
- A transport protein that moves glucose across cell membranes. It is named in MOTS-C study context.
- RUO
- Research use only. It is a lab-only boundary, not for human consumption, or for veterinary, medical or cosmetic use.
- COA
- Certificate of analysis. It is the batch paperwork that controls identity, purity, appearance and release.
FAQ
What are the most common questions about MOTS-C?
MOTS-C is a mitochondrial-derived peptide of 16 amino acids with the sequence MRWQEMGYIFYPRKLR. It is encoded in the 12S rRNA (MT-RNR1) region of mitochondrial DNA (Form Labs catalogue record). The common questions cover what a mitochondrial-derived peptide is. They also cover what the discovery paper found (Lee et al., 2015), and whether human trials exist. They cover how MOTS-C relates to AMPK, exercise and ageing, and how it differs from humanin. Form Labs supplies reference material for research use only.
MOTS-C is a mitochondrial-derived peptide of 16 amino acids (sequence MRWQEMGYIFYPRKLR). It is encoded within the 12S rRNA (MT-RNR1) region of mitochondrial DNA. It is studied in cell and animal research for mitochondrial biology and the AMPK energy pathway.
A mitochondrial-derived peptide (MDP) is a small peptide encoded inside mitochondrial DNA instead of the cell nucleus. Lee and colleagues first described MOTS-C in 2015 in Cell Metabolism. They found it in a short open reading frame in the mitochondrial 12S rRNA gene. It is one of a small MDP family that also includes humanin.
Lee et al. (2015) reported AMPK pathway observations in cells and more insulin sensitivity in mice. The paper included no human data.
Reynolds et al. (2021) measured the body's own MOTS-C after cycling in 10 healthy men. Kumagai et al. (2024) reported genetic links. Du et al. (2018) reported circulating MOTS-C measures. These are observational or genetic records. They are not clinical intervention results for native MOTS-C.
Lee et al. (2015) reported a link between MOTS-C, folate/one-carbon metabolism and AMPK in cell and mouse models. The study included no human data.
Reynolds et al. (2021) reported differences in running capacity and physical performance in aged mice. In a separate observation, the body's own MOTS-C rose after cycling in 10 healthy men. They did not receive MOTS-C. The lifespan trend in mice was not significant. The animal and human observations stay separate.
Kim and colleagues (2018) reported that, under glucose restriction, MOTS-C moves from the cytoplasm into the cell nucleus. There it helps regulate stress and antioxidant response genes (through NRF2/AMPK). This was a cell culture study in human cell lines. It describes how the peptide behaves in cells under stress. It is not a human or animal outcome.
No. MOTS-C and humanin are both mitochondrial-derived peptides, but they are different molecules. They are encoded by different parts of mitochondrial DNA (MOTS-C from the 12S rRNA / MT-RNR1 region). They are studied for overlapping but distinct roles in metabolism and stress signalling. MOTS-C is a peptide of 16 amino acids, sequence MRWQEMGYIFYPRKLR.
"For research use only" means MOTS-C is supplied strictly for lab research. It is not for human or veterinary consumption, medical use, or cosmetic use. This guide is an educational summary of third-party published research that Form Labs did not conduct. It is not medical advice or a product claim.
MOTS-C acts on the AMPK pathway. The World Anti-Doping Agency (WADA) prohibits AMPK activators as metabolic modulators (category S4) at all times in sport. Athletes under anti-doping rules should confirm MOTS-C's current status directly with WADA. Form Labs supplies MOTS-C for lab research only, not for human use.
References
Every figure, sourced.
Educational references to third-party literature. Form Labs is unaffiliated with the study authors.
The 2015 discovery paper identifying MOTS-C and linking it to the AMPK pathway and insulin sensitivity in mice. Lee C, Zeng J, Drew BG, et al. Cell Metabolism, 2015.
DOICell-culture study of MOTS-C moving into the nucleus under glucose restriction to regulate stress-response genes. Kim KH, Son JM, Benayoun BA, Lee C. Cell Metabolism, 2018.
DOIMouse and small human exercise study of MOTS-C, physical performance and aging. Reynolds JC, Lai RW, Woodhead JST, et al. Nature Communications, 2021; 12: 470.
DOIMouse, cell and human genetic-association study linking MOTS-C to CK2 binding and to muscle and metabolic traits. Kumagai H, Kim SJ, Miller B, et al. iScience, 2024; 27: 111212.
DOIHuman observational study of circulating MOTS-C against obesity and insulin-resistance markers in young people. Du C, Zhang C, Wu W, et al. Pediatric Diabetes, 2018.
DOIReview of MOTS-C as a mitochondrial-derived peptide regulating muscle and fat metabolism. Lee C, Kim KH, Cohen P. Free Radical Biology and Medicine, 2016.
DOIReview of mitochondrial-derived peptides in aging and age-related disease. Kim et al. The Journal of Physiology, 2017.
DOIReview of MOTS-C as a candidate for metabolic disorders. Wan et al. Journal of Translational Medicine, 2023.
DOIReview of MOTS-C in metabolic homeostasis and longevity. Mohtashami et al. International Journal of Molecular Sciences, 2022.
DOIReview of the role of MOTS-C in metabolic diseases. Zheng et al. Frontiers in Endocrinology, 2023.
DOICitations are provided for education only. No therapeutic, weight-loss, or efficacy claims are made.
How we produce these guides
These guides are written and maintained in-house by the Form Laboratories research team. They summarise published literature and link to the cited papers. Form Laboratories did not run those studies. They are not authored by a named clinician and are not medical advice.
Findings remain tied to the study population, model and limits. Cell and animal observations remain separate from clinical results. Everything we supply is research-use-only reference material, not for people or animals.
The product
Form Laboratories - MOTS-C
Ready to see MOTS-C?
- Check available reports and the tests they cover.
- Compare the listed compound, amount and lot with the report.
- Ships from Perth via Australia Post or CouriersPlease in plain packaging.
Related catalogue records
Compare nearby catalogue records.
These nearby records stay inside the research-only catalogue.
Research-use-only catalogue
Continue to the product record.
Review lot-facing product details, pricing, and checkout boundaries on the matching product page.
View MOTS-C - from $69.00 AUD